Cargando…

Depression in Patients with Mastocytosis: Prevalence, Features and Effects of Masitinib Therapy

Depression in patients with mastocytosis is often reported but its prevalence and characteristics are not precisely described. In addition, the impact of therapies targeting mast cells proliferation, differentiation and degranulation on psychic symptoms of depression have never been investigated. Ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moura, Daniela Silva, Sultan, Serge, Georgin-Lavialle, Sophie, Pillet, Nathalie, Montestruc, François, Gineste, Paul, Barete, Stéphane, Damaj, Gandhi, Moussy, Alain, Lortholary, Olivier, Hermine, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198767/ https://www.ncbi.nlm.nih.gov/pubmed/22031830 http://dx.doi.org/10.1371/journal.pone.0026375

Ejemplares similares

Evidence for Cognitive Impairment in Mastocytosis: Prevalence, Features and Correlations to Depression
por: Moura, Daniela Silva, et al.
Publicado: (2012)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Neuroprotective effect of masitinib in rats with postischemic stroke
por: Kocic, Ivan, et al.
Publicado: (2014)

Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients
por: Rouet, Audrey, et al.
Publicado: (2016)

A French National Survey on Clotting Disorders in Mastocytosis
por: Carvalhosa, Ana B., et al.
Publicado: (2015)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Neuroimaging evidence of brain abnormalities in mastocytosis
por: Boddaert, N, et al.
Publicado: (2017)

ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
por: Damaj, Gandhi, et al.
Publicado: (2014)

Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis
por: Hermine, Olivier, et al.
Publicado: (2008)

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
por: Tebib, Jacques, et al.
Publicado: (2009)

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis
por: Mora, Jesus S., et al.
Publicado: (2021)

Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset
por: Lanternier, Fanny, et al.
Publicado: (2008)

Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
por: Humbert, Martine, et al.
Publicado: (2010)

Mast cell sarcoma: new cases and literature review
por: Monnier, Jilliana, et al.
Publicado: (2016)

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial
por: Vermersch, Patrick, et al.
Publicado: (2022)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial
por: Davidescu, Lavinia, et al.
Publicado: (2022)

Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive
por: Joris, Magalie, et al.
Publicado: (2012)

Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
por: Dubois, Bruno, et al.
Publicado: (2023)

Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats
por: Belin-Rauscent, A., et al.
Publicado: (2018)

More about masitinib
por: Walker, Ulrich A
Publicado: (2009)

Targeted Treatment Options in Mastocytosis
por: Vaes, Mélanie, et al.
Publicado: (2017)

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
por: Deplanque, G., et al.
Publicado: (2015)

Interaction of Masitinib with Organic Cation Transporters
por: Harrach, Saliha, et al.
Publicado: (2022)

Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis
por: Trias, Emiliano, et al.
Publicado: (2016)

Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature
por: Aouba, A., et al.
Publicado: (2015)

Recent advances in the understanding and therapeutic management of mastocytosis
por: Rossignol, Julien, et al.
Publicado: (2019)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Chronic myelomonocytic leukemia as a cause of fatal uncontrolled inflammation in familial Mediterranean fever
por: Awad, Fawaz, et al.
Publicado: (2015)

Masitinib Inhibits Hepatitis A Virus Replication
por: Sasaki-Tanaka, Reina, et al.
Publicado: (2023)

Impact des maladies auto-immunes/auto-inflammatoires rares et de leur traitement sur la sévérité de l’infection à SARS-CoV-2 : à propos de 691 patients de la cohorte française FAI(2)R
por: Georgin-Lavialle, S.
Publicado: (2020)

ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
por: Petrov, Dmitry, et al.
Publicado: (2017)

Commentary: ‘Case Report: A Rare Case of Elderly-Onset Adult Onset Still’s Disease in a Patient With Systemic Lupus Erythematous’
por: Delplanque, Marion, et al.
Publicado: (2022)

Response letter to “Latent class analysis of 216 patients with adult-onset Still’s disease” by Sugiyama et al.
por: Delplanque, Marion, et al.
Publicado: (2022)

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference
por: Durojaye, Olanrewaju Ayodeji, et al.
Publicado: (2023)

The Effectiveness and Safety of Pharmaceutical-Grade Cannabidiol in the Treatment of Mastocytosis-Associated Pain: A Pilot Study
por: Rossignol, Julien, et al.
Publicado: (2023)

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
por: Milovancev, Milan, et al.
Publicado: (2016)

The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review
por: Hentgen, Véronique, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lt6h9hiqs3tl2msu370b2q7jai